CCND3 and hematopoietic and lymphoid cell neoplasm: The subset includes CCND3, whose transcription activated by ZNF224 causes deregulated proliferation of CLL cells (Busiello et al., 2017), TCL1A and DDR1 both overexpressed in CLL and other hematological cancers and correlated with disease progression and adverse prognosis (Herling et al., 2009; Cader et al., 2013; Guo et al., 2019; Sidhu et al., 2021); in particular, TCL1A, augmented in most B-cell tumors, has been proposed as a potential predictive marker of outcome following treatment in CLL patients (Browning et al., 2007).